Oral agar for the treatment of hyperbilirubinema in neonates born at term. A randomized double blind clinical trial
Phase 2
- Conditions
- eonatal jaundice.Neonatal jaundice due to unspecified causes
- Registration Number
- IRCT138902153250N3
- Lead Sponsor
- Kerman University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Term neonates admitted with non-hemolytic jaundice.All cases were otherwise healthy, breast fed, full term neonates with birth weight more than 2500g, and TSB of 13-25 mg/dl.
Exclusion criteria: Infants with any hemolytic disease (Rh or ABO incompatibility), sepsis or signs of dehydration such as decreasing neonatal reflexes and lethargy or unwillingness to feeding, those who were older than 10 days and infants who required exchange transfusion.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Decreased serum bilirubin level. Timepoint: 6, 12, 24 hours after starting phototherapy. Method of measurement: Auto analyzer, Selectra E.
- Secondary Outcome Measures
Name Time Method Decreased duration of phototherapy. Timepoint: During hospitalization. Method of measurement: Calculating the hours of phototherapy.